Apellis receives J-code for Syfovre

Fact checked byChristine Klimanskis, ELS

Key takeaways:

Syfovre received a permanent, product-specific J-code, which will go into effect Oct. 1.
The code for Syfovre is J2781.

CMS assigned a permanent, product-specific J-code for Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Apellis Pharmaceuticals.

The code, J2781, goes into effect Oct. 1.

Generic Industry News infographic — CMS assigned a permanent, product-specific J-code for Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Apellis Pharmaceuticals.

The FDA approved Syfovre (pegcetacoplan injection) in February, making it the first approved treatment for geographic atrophy (GA).

“The permanent J-code is a significant milestone that will help ensure accurate and efficient reimbursement of Syfovre in all treatment settings, building on our goal of bringing this important treatment to GA patients in need,” Adam Townsend, chief commercial officer of Apellis, said in the release.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Apellis receives J-code for Syfovre

Key takeaways:

Related Content